<DOC>
	<DOCNO>NCT01193140</DOCNO>
	<brief_summary>To evaluate safety tolerability veliparib/TMZ combination subject solid tumor .</brief_summary>
	<brief_title>To Evaluate Safety Veliparib Combination With Temozolomide Subjects With Solid Tumors</brief_title>
	<detailed_description>An extension study evaluate safety veliparib combination temozolomide subject solid tumor</detailed_description>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<criteria>Inclusion Criteria 1 . Subject complete study participation Study M11846 2 . Eastern Cooperative Oncology Group ( ECOG ) performance score 0 2 . 3 . Subject must adequate hematologic , renal hepatic function per institutional normal range follow : • Bone Marrow : Absolute neutrophil count ( ANC ≥ 1,500/mm3 ( 1.5 × 109/L ) ; Platelets ≥ 100,000/mm3 ( 100 × 109/L ) ; Hemoglobin ≥ 9.5 g/dL ( 1.4 mmol/L ) ; • Renal function : Serum creatinine ≤ 1.5 × upper limit normal ( ULN ) range OR creatinine clearance ≥ 50 mL/min/1.73 m2 subject creatinine level institutional normal ; • Hepatic function : AST ALT ≤ 2.5 × ULN range . For subject liver metastasis , AST ALT &lt; 5 × ULN range ; Bilirubin ≤ 1.5 × ULN range . • Partial Thromboplastin Time ( PTT ) must ≤ 1.5 × ULN range INR &lt; 1.5 . Subjects anticoagulant therapy ( Coumadin ) appropriate PTT INR determine Investigator . 4 . Women childbearing potential must agree use adequate contraception ( one follow list ) prior study entry , duration study participation 90 day follow completion therapy . Women childbearing potential must negative serum pregnancy test within 28 day prior initiation treatment negative urine pregnancy test Cycle 1 Day 1 and/or post menopausal woman must amenorrheic least 12 month consider nonchildbearing potential . • Total abstinence sexual intercourse ( minimum one complete menstrual cycle ) ; • Vasectomized partner ; • Hormonal contraceptive ( oral , parenteral transdermal ) least 3 month prior study drug administration ; • Doublebarrier method ( condom , contraceptive sponge , diaphragm vaginal ring spermicidal jelly cream ) ; • IUD ( Intrauterine Device ) . Exclusion Criteria 1 . Subject receive anticancer agent ( ) investigational agent ( except veliparib ) within 28 day prior study drug administration . Subjects recover within one grade level ( exceed grade 2 ) baseline follow significant adverse event toxicity attribute previous anticancer treatment exclude . 2 . Subject undergone major surgery within previous 28 day prior study drug administration . 3 . Subject receive radiotherapy within 28 day prior study drug administration . 4 . Clinically significant uncontrolled major medical condition ( ) include limited : • Active uncontrolled infection ; • Symptomatic congestive heart failure ; • Unstable angina pectoris cardiac arrhythmia ; • Psychiatric illness/social situation would limit compliance study requirement ; • Any medical condition , opinion Study Investigator , place subject unacceptably high risk toxicity . 5 . Subject pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>veliparib</keyword>
	<keyword>relapsed refractory tumor</keyword>
	<keyword>Temodar</keyword>
	<keyword>temozolomide</keyword>
	<keyword>ABT-888</keyword>
	<keyword>Solid Tumors</keyword>
</DOC>